Clinical trials: SARS CoV 2 Infection
Lower Respiratory Tract Infection, Parainfluenza
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
- Conditions
- Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
- Trial name
- NCT03808922
- Testing
- DAS181, DAS181 COVID-19, DAS181 OL
- Where
- 28 sites in United States, Australia and 3 more
- Volunteers
- 274 people
- Sponsor
- Ansun Biopharma, Inc.
SARS-CoV-2 Infection
Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
This is a Prospective, Randomized, Multi-center, Open label, Phase 1/2 study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2].
- Trial name
- PROTECT (NCT04834908)
- Testing
- Equine COVID-19 Antiserum, Standard of care
- Where
- India
- Volunteers
- 7 people
- Sponsor
- Bharat Serums and Vaccines Limited
COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
eVusheld Assessment reaL wORld Effectiveness in DoD Health System
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR DoD (NCT05569408)
- Testing
- EVUSHELD
- Where
- United States
- Volunteers
- 4,724 people
- Sponsor
- AstraZeneca
COVID-19 Virus Disease
Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease.
A Phase I dose-escalation study to test a new monoclonal antibody (called MAD0004J08) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease.
- Trial name
- MAD0004J08 (NCT04932850)
- Testing
- MAD0004J08
- Where
- 2 sites in Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Toscana Life Sciences Sviluppo s.r.l.
COVID-19 Vaccine
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
The objective of this clinical trial is to test a new vaccine against SARS-CoV-2 (ARVAC-CG) in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus.
- Trial name
- NCT05656508
- Testing
- ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)
- Where
- Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Laboratorio Pablo Cassara S.R.L.
COVID-19, Coronavirus
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.
- Conditions
- COVID-19, Coronavirus, Mortality
- Trial name
- IDENTIFY (NCT04423991)
- Testing
- COViage
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Dascena
COVID-19
A Study of Silmitasertib (CX-4945) in Healthy Subject
This is a Phase I single center, open-label, parallel design in 30 subjects to evaluate safety and tolerability of CX-4945 200mg QD, 200 mg BID and 400mg BID doses (10 subjects in each regimen) for continuously 5 days in healthy…
- Trial name
- NCT05817708
- Testing
- CX-4945
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Senhwa Biosciences, Inc.
Covid19
Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients
SARS-CoV-2 infection is a condition characterized by excessive leukocyte infiltration, massive release of chemokines, proteases and cytokines, the so-called "cytokine storm", which promote the inflammatory process and contribute…
- Trial name
- NCT04568876
- Testing
- Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension, Standard Therapy
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Epitech Group SpA
COVID-19
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine
This study is a randomized, placebo-controlled and open design, phase 4 clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.
- Trial name
- NCT04953325
- Testing
- Inactivated COVID-19 Vaccine, 23-valent pneumococcal polysaccharide vaccine, Inactivated Hepatitis A Vaccine
- Where
- China
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Covid19
Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19
A phase 2, placebo-controlled study of the safety and efficacy of STI-5656 (Abivertinib Maleate) in subjects hospitalized due to COVID-19
- Trial name
- NCT04528667
- Testing
- STI-5656
- Where
- Brazil
- Volunteers
- 396 people
- Sponsor
- Sorrento Therapeutics, Inc.
Post-Acute COVID19 Syndrome, Fatigue
Feasibility Study of Adhera® Fatigue Digital Program for Patients With Long COVID-related Fatigue
Adhera® Fatigue Digital Program (or AFDP) is a digital health program based on behavioral and emotional change techniques that provides personalized physical and emotional self-management support for patients with long…
- Trial name
- COVIDAI (NCT05631171)
- Testing
- Adhera® Fatigue Digital Program
- Where
- 2 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Adhera Health, Inc.
Viral Disease
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
- Trial name
- NCT04535167
- Testing
- PF-07304814
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 26 people
- Sponsor
- Pfizer
COVID-19
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815…
- Trial name
- NextCOVE (NCT05815498)
- Testing
- mRNA-1283.222, mRNA-1273.222, mRNA-1283.815
- Where
- 230 sites in United States, Canada and 2 more
- Volunteers
- 13,553 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2, COVID-19 Vaccines
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall…
- Trial name
- NCT06199934
- Testing
- Vaccination
- Where
- United States
- Volunteers
- 19,853,610 people
- Sponsor
- Pfizer
COVID-19 Pneumonia
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe…
- Trial name
- MARIPOSA (NCT04363736)
- Testing
- Tociliuzumab
- Where
- 24 sites in United States
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Coronavirus Disease 2019
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells)…
- Trial name
- NCT05107375
- Testing
- Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
INFLAMmatory BiomarkErs in COVID-19 Participants and Severity of Disease
Observational Study of the Association of Immunological and Inflammatory Biomarkers in COVID-19 Naïve and Infected Participants and Severity of Disease.
- Trial name
- INFLAME COVID (NCT05175846)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Trinitas Global, LLC
SARS-CoV 2 Infection, Covid19
Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19
This study objective is to collect tear and blood samples from individuals with positive SARS-COV2 diagnosis and test those samples for the presence of various SARS-COV2 viral antigens and autoantibodies.
- Trial name
- NCT04542980
- Testing
- SARS-CoV2 Autoantibody detection
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Namida Lab
COVID-19
Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study
This is a Randomized, double-blind, Placebo-Controlled, Phase II Clinical Study to evaluate SSD8432 in combination with Ritonavir in asymptomatic infections or mild/common safety study of efficacy and safety in adult subjects…
- Trial name
- NCT05373446
- Testing
- SSD8432 300mg, SSD8432 750mg
- Volunteers
- 72 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
COVID-19
Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial
The purpose of this study is to evaluate the safety of Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) after vaccination in people aged 18 and over.
- Trial name
- NCT06043388
- Testing
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.